Cite
HARVARD Citation
Porta, C. et al. (n.d.). Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries. Cancer medicine. pp. 1517-1526. [Online].